Gossamer Bio (GOSS) Receives a Buy From Piper Sandler
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9. Gossamer Bio is focused on developing
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
Express News | Gossamer Bio Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $9
Express News | Gossamer Bio Shares Are Trading Higher After Oppenheimer Initiated Coverage With an Outperform Rating and a Price Target of $9
Gossamer Bio Initiated at Outperform by Oppenheimer
Gossamer Bio Initiated at Outperform by Oppenheimer
Express News | Oppenheimer Initiates Coverage On Gossamer Bio With Outperform Rating, Announces Price Target of $9
Gossamer Bio(GOSS.US) Officer Buys US$250.28K in Common Stock
$Gossamer Bio(GOSS.US)$ Officer Hasnain Faheem purchased 372K shares of common stock on Jun 21, 2024 at an average price of $0.6728 for a total value of $250.28K.Source: Announcement What is statement
Gossamer Bio a New Outperform at Oppenheimer on Seralutinib for PAH
Bryan Giraudo Bought 21% More Shares In Gossamer Bio
Even if it's not a huge purchase, we think it was good to see that Bryan Giraudo, the COO & CFO of Gossamer Bio, Inc. (NASDAQ:GOSS) recently shelled out US$59k to buy stock, at US$0.59 per share. T
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0 million public offering.Kaival Brands priced its 3,921,50
Gossamer Bio(GOSS.US) Officer Buys US$59,110 in Common Stock
$Gossamer Bio(GOSS.US)$ Officer Giraudo Bryan purchased 100K shares of common stock on Jun 18, 2024 at an average price of $0.5911 for a total value of $59,110.Source: Announcement What is statement o
Gossamer Bio(GOSS.US) Officer Buys US$15,050 in Common Stock
$Gossamer Bio(GOSS.US)$ Officer Smith Robert Paul JR purchased 25,000 shares of common stock on Jun 17, 2024 at an average price of $0.602 for a total value of $15,050.Source: Announcement What is sta
Gossamer Bio Is Maintained at Buy by Goldman Sachs
Gossamer Bio Is Maintained at Buy by Goldman Sachs
Express News | Gossamer Bio Shares Are Trading Higher After Competitor Aerovate Therapeutics Reported Topline Results From the Phase 2b Portion of IMPAHCT Trial of AV-101 for Pulmonary Arterial Hypertension
Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8
Goldman Sachs analyst Paul Choi maintains $Gossamer Bio(GOSS.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 0.0% and a total
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersAutonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNC
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price target.
Express News | Gossamer Bio to Provide Updated Seralutinib Torrey Open-Label Extension Data at the American Thoracic Society 2024 International Conference